Ceftobiprole
From IDWiki
Background
Mechanism of Action
- Binds to and inhibits PBP-2a on MRSA
- Binds to and inhibits PBP-2x on penicillin-resistant Streptococcus pneumoniae
Spectrum of Activity
- Active against MRSA, ampicillin-susceptible Enterococcus, and penicillin-resistant Streptococcus pneumoniae, as well as aerobic Gram-negative bacteria similar to other third-generation cephalosporins
- Not active against Pseudomonas, ESBL-producers, or AmpC-producers
Pharmacokinetics and Pharmacodynamics
- Crosses into CSF adequately
Dosing
- Usual dose (CAP, SSTI): 500 mg IV q8h over 2 hours
- Staphylococcus aureus bacteremia: 500 mg IV q6h for 8 days followed by q8h
Renal Dosing
| CrCl | Usual Dose | High Dose (MRSA) |
|---|---|---|
| ≥50 | 500 mg q8h | 500 mg q6h for 8 days then q8h |
| 30 to <50 | 500 mg q12h | 500 mg q8h for 8 days then q12h |
| 15 to <30 | 250 mg q12h | 250 mg q8h for 8 days then q12h |
| <15 | 250 q24h | |
| IHD | 250 q24h (after dialysis when given on dialysis days) | |
Safety
Adverse Drug Reactions
- Nausea, diarrhea, neutropenia (4%), dysgeusia
